Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...

If approved, the six manufacturers – Dr Reddy’s Laboratories Limited, Emcure, Eva Pharma, Ferozsons Laboratories Limited, ...

Duckhorn (NAPA) to be acquired by Butterfly Equity in $1.95B all-cash deal, with shares jumping over 100% premarket.

The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health network — if he wins reelection. The top 5 highest-paid pharma CEOs all ...

Yes, the much-maligned Ozempic and related semaglutide medications, which induce satiety and have helped some conquer chronic obesity. This is—objectively—a positive thing. It should mostly go ...